CRISPR Therapeutics AG (CRSP)

In Q4 2025, CRISPR Therapeutics reported strong Casgevy revenue, leading to positive stock movement. In March 2026, the company announced a convertible senior notes offering, which can lead to short-term stock price adjustments. In Q1 2026, CRISPR Therapeutics reported a wider-than-expected loss per share, but the stock gained due to commercial progress for Casgevy and a strengthened cash position. Analysts have maintained a generally positive outlook, and ARK Investment Management and UBS Group increased their stakes. News of a competing sickle cell stock receiving approval could introduce competitive pressures.

Demand for CRISPR Therapeutics AG's products and services is not subject to typical seasonal fluctuations, as gene therapies address urgent medical needs driven by patient eligibility, disease prevalence, regulatory approvals, and the establishment of treatment centers and reimbursement pathways.

CRISPR Therapeutics AG is a Swiss-American biotechnology company focused on developing gene-based medicines using its CRISPR/Cas9 gene editing platform. Its lead approved product is CASGEVY™ (exagamglogene autotemcel), a gene-edited cell therapy for treating severe sickle cell disease and transfusion-dependent beta-thalassemia. The company also has CAR T cell therapies like CTX112 and CTX131, in vivo gene editing programs such as CTX310 and CTX320, regenerative medicine therapies like CTX211 and CTX213, and partnered programs including SRSD107.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with U.S. research and development facilities in Boston and San Francisco. It also has business offices in London, United Kingdom, and supports clinical trials across North America and Europe.

CRISPR Therapeutics' brand reputation has been positively influenced by the FDA approval and commercialization of Casgevy, as well as positive clinical data for pipeline candidates. Challenges include the high cost and logistical complexities of gene therapies, competition, intellectual property uncertainty, and the company's current unprofitability.

CRISPR Therapeutics AG has significant institutional ownership, with 79.31% of its stock held by institutional shareholders, including ARK Investment Management LLC, BlackRock, Inc., and Glaxosmithkline Plc. Insider selling by executives has been noted in the past 90 days.